About
NanoGuard Technologies develops cold plasma (HVACP) systems for low-temperature sterilization and microbial/mycotoxin reduction in medical device and food/agricultural applications. Its patented technology achieves a 6.0-log reduction of Bacillus atrophaeus spores and is positioned as an alternative to ethylene oxide sterilization methods.
Explore NanoGuard Technologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.